Published on 13 Dec 2021 on Insider Monkey via Yahoo Finance

Hedge Funds Are Selling Dicerna Pharmaceuticals Inc (DRNA)

Is Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to work. The top picks of these firms have historically outperformed the market when we account for known risk factors, making them very valuable investment ideas.

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) was in 26 hedge funds' portfolios at the end of September. The all time high for this statistic is 35. DRNA investors should be aware of a decrease in hedge fund interest recently. There were 27 hedge funds in our database with DRNA positions at the end of the second quarter. Our calculations also showed that DRNA isn't among the 30 most popular stocks among hedge funds (click for Q3 rankings).

At Insider Monkey, we scour multiple sources to uncover the next great investment idea. For example, lithium prices have more than doubled over the past year, so we go through lists like the 10 best EV stocks to pick the next Tesla that will deliver a 10x return. Even though we recommend positions in only a tiny fraction of the companies we analyze, we check out as many stocks as we can. Now let's take a gander at the key hedge fund action surrounding Dicerna Pharmaceuticals Inc (NASDAQ:DRNA).